Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengda Pharmaceuticals Co's revenue for the
three
months ended in Mar. 2026 was ¥128.2 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥458.3 Mil.
Chengda Pharmaceuticals Co's Revenue per Share for the
three
months ended in Mar. 2026 was ¥0.85.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.03.
Warning Sign:
Chengda Pharmaceuticals Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Chengda Pharmaceuticals Co was 48.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 12 years, Chengda Pharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 24.10% per year. The lowest was -63.60% per year. And the median was -0.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Chengda Pharmaceuticals Co Revenue Related Terms
Chengda Pharmaceuticals Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's Revenue distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥458.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengda Pharmaceuticals Co (SZSE:301201) has a Revenue of ¥458.3 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Chengda Pharmaceuticals Co and its competitors.
Is Chengda Pharmaceuticals Co's Revenue too high?
Chengda Pharmaceuticals Co's current Revenue is ¥458.3 Mil. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's Revenue compare to ZTS?
Chengda Pharmaceuticals Co's Revenue of ¥458.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Chengda Pharmaceuticals Co and its competitors. Chengda Pharmaceuticals Co's current Revenue is ¥458.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Fairly Valued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥29.75 — trading 2.3% below its estimated fair value. The current Revenue is ¥458.3 Mil. Chengda Pharmaceuticals Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current Revenue is ¥458.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥29.75 is trading 2.3% below its estimated GF Value™ of ¥30.45.
GuruFocus considers Chengda Pharmaceuticals Co to be Fairly Valued.
Key valuation signals for SZSE:301201:
Revenue: ¥458.3 Mil
GF Value™: ¥30.45 vs. price of ¥29.75 (2.3% below fair value)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
78GF Score
Get the complete analysis for SZSE:301201
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
